Cerebrospinal Fluid Levels of Amyloid Beta 1–43 in Patients with Amnestic Mild Cognitive Impairment or Early Alzheimer’s Disease: A 2-Year Follow-Up Study

Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment

(2018) Niklas Mattsson et al.   JOURNAL OF ALZHEIMERS DISEASE

Evaluation of CSF Biomarkers as Predictors of Alzheimer's Disease: A Clinical Follow-Up Study of 4.7 Years

(2017) Joakim Hertze et al.   JOURNAL OF ALZHEIMERS DISEASE

Progression of mild cognitive impairment to dementia due to AD in clinical settings

(2015) Karim Tifratene et al.   NEUROLOGY

The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative

(2014) José Luis Molinuevo et al.   Alzheimers & Dementia

Biological heterogeneity in ADNI amnestic mild cognitive impairment

(2014) Jasmine Nettiksimmons et al.   Alzheimers & Dementia

The C-Terminal Threonine of Aβ43 Nucleates Toxic Aggregation via Structural and Dynamical Changes in Monomers and Protofibrils

(2014) Alexander E. Conicella et al.   BIOCHEMISTRY

Apolipoprotein E  2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort

(2014) G. Berge et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

(2014) Bruno Dubois et al.   LANCET NEUROLOGY

Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease

(2014) Ronald Lautner et al.   JAMA Psychiatry

Aβ43 Is the Earliest-Depositing Aβ Species in APP Transgenic Mouse Brain and Is Converted to Aβ41 by Two Active Domains of ACE

(2013) Kun Zou et al.   AMERICAN JOURNAL OF PATHOLOGY

The Diagnostic Value of CSF Amyloid-β43 in Differentiation of Dementia Syndromes

(2013) Kim Bruggink et al.   Current Alzheimer Research

The Pathogenic Aβ43 Is Enriched in Familial and Sporadic Alzheimer Disease

(2013) Anna Sandebring et al.   PLoS One

Cerebrospinal Fluid Levels ofβ-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia

(2012) Peder Buchhave   ARCHIVES OF GENERAL PSYCHIATRY

The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Guy M. McKhann et al.   Alzheimers & Dementia

The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease

(2011) Marilyn S. Albert et al.   Alzheimers & Dementia

Potent amyloidogenicity and pathogenicity of Aβ43

(2011) Takashi Saito et al.   NATURE NEUROSCIENCE

Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain

(2009) Tero Tapiola et al.   ARCHIVES OF NEUROLOGY

CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment

(2009) Niklas Mattsson   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Aβ43 is more frequent than Aβ40 in amyloid plaque cores from Alzheimer disease brains

(2009) Hedvig Welander et al.   JOURNAL OF NEUROCHEMISTRY

Relationship of Cerebrospinal Fluid Markers to 11C-PiB and 18F-FDDNP Binding

(2009) N. Tolboom et al.   JOURNAL OF NUCLEAR MEDICINE